Kura Oncology Inc (NASDAQ:KURA) — Market Cap & Net Worth
Market Cap & Net Worth: Kura Oncology Inc (KURA)
Kura Oncology Inc (NASDAQ:KURA) has a market capitalization of $1.01 Billion ($1.01 Billion) as of September 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8861 globally and #2533 in its home market, demonstrating a -14.72% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kura Oncology Inc's stock price $11.30 by its total outstanding shares 88960619 (88.96 Million). Also see how large is Kura Oncology Inc's balance sheet for a full breakdown of the balance sheet.
Kura Oncology Inc Market Cap History: 2015 to 2026
Kura Oncology Inc's market capitalization history from 2015 to 2026. Data shows change from $747.27 Million to $1.01 Billion (-1.94% CAGR). Also see Kura Oncology Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Kura Oncology Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.04% | #255 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.00% | #952 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.05% | #148 of 263 |
Weight: Kura Oncology Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Kura Oncology Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kura Oncology Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Kura Oncology Inc share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
13.70x
Kura Oncology Inc's market cap is 13.70 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $774.85 Million | $53.88 Million | -$173.98 Million | 14.38x | N/A |
| 2025 | $924.30 Million | $67.48 Million | -$278.67 Million | 13.70x | N/A |
Competitor Companies of KURA by Market Capitalization
Companies near Kura Oncology Inc in the global market cap rankings as of September 16, 2026. Review KURA goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Kura Oncology Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Kura Oncology Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Kura Oncology Inc's market cap moved from $747.27 Million to $ 1.01 Billion, with a yearly change of -1.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.01 Billion | +8.76% |
| 2025 | $924.30 Million | +19.29% |
| 2024 | $774.85 Million | -39.43% |
| 2023 | $1.28 Billion | +15.87% |
| 2022 | $1.10 Billion | -11.36% |
| 2021 | $1.25 Billion | -57.13% |
| 2020 | $2.91 Billion | +137.53% |
| 2019 | $1.22 Billion | -2.07% |
| 2018 | $1.25 Billion | -8.24% |
| 2017 | $1.36 Billion | +159.32% |
| 2016 | $524.87 Million | -29.76% |
| 2015 | $747.27 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Kura Oncology Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.01 Billion USD |
| MoneyControl | $1.01 Billion USD |
| MarketWatch | $1.01 Billion USD |
| marketcap.company | $1.01 Billion USD |
| Reuters | $1.01 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kura Oncology Inc
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapi… Read more